Renovaro Past Earnings Performance
Past criteria checks 0/6
Renovaro's earnings have been declining at an average annual rate of -37.2%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-37.2%
Earnings growth rate
-25.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -117.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Renovaro makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -116 | 22 | 3 |
| 30 Jun 24 | 0 | -81 | 25 | 3 |
| 31 Mar 24 | 0 | -88 | 21 | 3 |
| 31 Dec 23 | 0 | -41 | 19 | 2 |
| 30 Sep 23 | 0 | -41 | 19 | 2 |
| 30 Jun 23 | 0 | -40 | 15 | 4 |
| 31 Mar 23 | 0 | -107 | 16 | 5 |
| 31 Dec 22 | 0 | -109 | 15 | 6 |
| 30 Sep 22 | 0 | -111 | 14 | 8 |
| 30 Jun 22 | 0 | -113 | 14 | 8 |
| 31 Mar 22 | 0 | -41 | 13 | 19 |
| 31 Dec 21 | 0 | -38 | 12 | 19 |
| 30 Sep 21 | 0 | -35 | 10 | 18 |
| 30 Jun 21 | 0 | -27 | 8 | 16 |
| 31 Mar 21 | 0 | -13 | 7 | 5 |
| 31 Dec 20 | 0 | -11 | 7 | 6 |
| 30 Sep 20 | 0 | -10 | 7 | 5 |
| 30 Jun 20 | 0 | -11 | 7 | 5 |
| 31 Mar 20 | 0 | -6 | 7 | 4 |
| 31 Dec 19 | 0 | -7 | 8 | 2 |
| 30 Sep 19 | 0 | -22 | 9 | 3 |
| 30 Jun 19 | 0 | -18 | 8 | 2 |
| 31 Mar 19 | 0 | -21 | 8 | 2 |
| 31 Dec 18 | 0 | -21 | 8 | 2 |
| 30 Sep 18 | 0 | -6 | 6 | 1 |
| 30 Jun 18 | 0 | -6 | 5 | 1 |
| 31 Mar 18 | 0 | -4 | 4 | 1 |
Quality Earnings: 2Q5 is currently unprofitable.
Growing Profit Margin: 2Q5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2Q5 is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.
Accelerating Growth: Unable to compare 2Q5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2Q5 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2Q5 has a negative Return on Equity (-117.94%), as it is currently unprofitable.